North America Nuclear Imaging Market Industry Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The North American nuclear imaging market is one of the most mature diagnostic imaging markets globally, anchored by the United States and supported by well-established reimbursement frameworks and a dense network of hospitals and imaging centers. The region accounts for the largest share of worldwide nuclear imaging revenue, reflecting high procedure volumes, early adoption of new radiotracers, and significant capital investment in hybrid PET/CT and SPECT/CT systems. Equipment, radiopharmaceuticals, and services together form the three principal revenue streams within the market.

• •North America holds roughly 38 to 53 percent of global nuclear medicine and nuclear imaging revenue, depending on the segment measured.
• •The U.S. market alone accounts for the bulk of regional spending, with Canada and Mexico contributing smaller but growing shares.
• •Hybrid imaging modalities, particularly PET/CT and SPECT/CT, represent the dominant equipment category.

The rising prevalence of cancer, cardiovascular disease, and neurodegenerative disorders such as Alzheimer's disease is increasing demand for non-invasive functional imaging that can detect disease earlier than anatomical modalities. The expansion of approved radiopharmaceuticals, including PSMA-based agents for prostate cancer and amyloid and tau tracers for dementia, is broadening clinical applications. An aging population, growing acceptance of theranostics, and ongoing replacement of older analog gamma cameras with digital SPECT systems are also supporting steady market expansion.

• •Cancer and cardiovascular disease remain the leading indications driving PET and SPECT procedure volumes.
• •Approval of new disease-specific radiotracers is expanding the addressable patient population.
• •Aging demographics in the U.S. and Canada are increasing the long-term need for diagnostic imaging.

By modality, PET and PET/CT systems generate the largest share of revenue, followed by SPECT and SPECT/CT, with standalone planar gamma cameras representing a declining segment. By application, oncology accounts for the majority of PET procedure volume, while cardiology continues to dominate SPECT utilization. Geographically, the United States represents the overwhelming majority of North American revenue, with Canada representing a smaller but stable market and Mexico showing gradual growth as private healthcare investment expands.

• •Oncology is the leading application for PET, while cardiology remains central to SPECT demand.
• •The United States accounts for the largest share of regional nuclear imaging revenue.
• •Replacement of older analog systems with digital SPECT/CT cameras is a notable equipment sub-trend.

What are the recent trends and outlook?

Digital SPECT/CT adoption, total-body and digital PET technology, and AI-enabled image reconstruction are reshaping clinical workflows and improving throughput in imaging centers. Theranostics, the pairing of diagnostic imaging with targeted radionuclide therapy, is the most consequential growth frontier, with prostate cancer and neuroendocrine tumor applications leading adoption. Over the medium term, the North American market is expected to continue expanding at a mid-single-digit annual pace, supported by new tracer approvals, growing theranostic demand, and ongoing equipment refresh cycles.

• •Digital PET and total-body PET systems are gaining traction in high-volume academic centers.
• •Theranostics is emerging as the most significant long-term growth opportunity.
• •AI-driven reconstruction and quantification tools are improving scanner efficiency and diagnostic accuracy.